Aspira Womens Health Inc Stock Price, News & Analysis

Aspira Women's Health (OTCQB:AWHL) has secured a total equity capital infusion of $3.06 million through a combination of private placement and warrant exercise. The company raised $2.95 million through a Unit Purchase private placement at $0.45 per unit, consisting of common stock and warrants, plus $112,500 from warrant exercises.

The private placement resulted in the issuance of 6,550,000 common shares and 4,912,500 new warrants with a $0.75 strike price and 5-year term. The funds will support Aspira's commercial activities and working capital needs as the company continues to develop innovative solutions for ovarian cancer and endometriosis diagnostics.

Aspira Women's Health (OTCQB:AWHL), an AI-enhanced women's health diagnostics company, has appointed Brian Hungerford as Chief Financial Officer effective September 2, 2025. Hungerford brings over 20 years of experience in accounting, finance, and biotechnology sectors.

The new CFO is a Certified Public Accountant (CPA) and Chartered Global Management Accountant (CGMA) with extensive experience in SEC reporting, project management, and process improvements. His previous roles include positions at Constellation Energy Group, Dynegy, and most recently as CFO of Kiromic Biopharma, where he managed financial operations for their cancer treatment R&D programs.

Aspira Women's Health (OTCQB:AWHL) reported its Q2 2025 financial results, showing stable performance amid significant business model transformation. Total product revenue reached $2.404 million in Q2 2025, compared to $2.423 million in Q2 2024. The company achieved a 12% year-over-year increase in average unit prices for its commercial portfolio.

Key achievements include a 156% increase in sales per FTE, improved gross margins of 66.1% (up from 57.6%), and a 41% reduction in operating cash burn. Operating expenses decreased by 31% to $8.1 million for H1 2025. The company maintained revenue stability despite reducing its sales team from 19 to 7 specialists, while focusing on relationships with large healthcare systems and IDNs.

Aspira Women's Health (QTCQB:AWHL), an AI-enhanced women's health diagnostics company, has appointed Jane Pine Wood to its Board of Directors, effective July 11, 2025.

Wood brings extensive healthcare legal expertise, currently serving as Counsel at McDonald Hopkins, LLC since 2024. She previously held the position of Chief Legal Counsel at BioReference Health, LLC, a clinical diagnostic laboratory focused on oncology, urology, and women's health. Her nearly three-decade career at McDonald Hopkins included building one of the country's largest laboratory and pathology client portfolios.

Aspira Women's Health (AWHL) has partnered with Dorsata to launch an adnexal mass clinical decision support module, expanding access to over 300 women's health practices and 1.5M+ patients. The module, live since June 2, 2025, integrates Aspira's Ova1Plus® and OvaWatch® tests into Dorsata's platform, which serves 700+ providers across 20 states. Currently performing 24,000 tests annually with 4,000 active prescribing providers, this partnership represents a 17.5% increase in provider access. With an estimated 1.2 million ovarian mass cases annually among 30,000 US OBGYNs, the partnership creates approximately 28,000 new opportunities for test implementation. The module streamlines the ordering process and documentation of Aspira's OvaSuite tests within providers' daily workflows, enhancing clinical efficiency and patient care.

Aspira Women's Health (AWHL) announces the termination of its ARPA-H Sprint Program partnership for the development of ENDOinform, a non-invasive blood-based test for endometriosis diagnosis. The original $10 million contract, announced in October 2024, was divided into eight payments, with $3.5 million already received through two milestone payments. On June 9, 2025, ARPA-H terminated the contract citing unmet specifications for Milestone 3. Despite the setback, CEO Mike Buhle maintains confidence in the team's achievement of requirements and commits to continuing the ENDOinform program development, targeting completion in 2026. The test combines protein and microRNA biomarkers with patient data using AI algorithms to aid in endometriosis diagnosis.

Aspira Women's Health reported its Q1 2025 financial results, showing notable improvements under new leadership. Revenue grew 5.9% to $2.28M vs Q1 2024, driven by price increases. The company achieved a 94% increase in sales per FTE and improved gross profit by 28.5% to $1.6M, with margins expanding to 68.5% from 56.4%. Operating expenses decreased by 19% to $4.8M, while cash burn reduced 30% to $3.1M. Under new CEO Mike Buhle's leadership, current liabilities decreased by 30.1% to $3.8M, and cash position strengthened to $3.3M from $1.8M in December 2024. The company remains focused on developing ENDOInform™, with updates expected by end of 2025.

Aspira Women's Health Inc. (OTCQB:AWHL), an AI-enhanced bio-analytics women's health company, has completed its transition to the OTCQB markets exchange, with trading beginning on May 7, 2025. CEO Mike Buhle emphasized this move as a positive step for shareholders, highlighting the company's strategic focus on cost reduction, controlled capital raises to minimize dilution, and leveraging non-dilutive capital sources for short-term business objectives.

Aspira Women's Health (OTC PINK:AWHL) has successfully submitted its third milestone under the $10 million ARPA-H award program, making it eligible for an additional $1.5 million payment expected in Q2 2025. The milestone focused on analytical development steps, including a biomarker technical report and voice of customer study framework for their ENDOinform™ program.

The company has already secured $3.5 million through three milestone submissions and anticipates receiving $2.0 million in fourth and fifth milestone payments by end-2025, with the remaining $3.0 million expected in 2026. The funding supports Aspira's development of an AI-enabled multi-marker blood test for endometriosis detection, leveraging technology from their successful ovarian cancer risk assessment tests.